Given the lack of pharmacological agents that directly improve renal function in patients with HF, long-term studies with DPPIV inhibitors are warranted to ascertain whether the renoprotective effects of DPPIV inhibition ultimately translate into improved clinical outcomes. Here, DPP4 is linked to hydrops fetalis.